Swedish researchers analyzed needle core biopsy slides from men with prostate cancer and found that using an artificial intelligence system can help detect and grade prostate cancer, as well as distinguish benign biopsy cores from malignant ones. The findings, published in The Lancet Oncology, also showed that the association between the AI-predicted cancer length and the one assigned by reporting pathologists was 0.96 for the independent data set and 0.87 for the external validation data set.
Study shows benefits of using AI in prostate cancer
Sign up for SNMMI SmartBrief
Nuclear medicine and molecular imaging news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.